Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.
Revision as of 10:43, 23 May 2026 by MDElliottMD (talk | contribs) (home-claude category backfill (parser-claude gap closure))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Docusate (sodium or calcium)
Colace (sodium), Surfak (calcium); many generics OTC

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Pharmacy
Starting dose
100-200 mg PO once or twice daily; pediatric weight-based
Preparations
50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC
US FDA Max
~500 mg/d typical
Pharmacology
Routes
Oral, rectal
Onset
1-3 days
Duration
Hours
Half-life
Not meaningfully described
Bioavailability
Local action; minimal systemic effect
Pregnancy
Generally considered safe.[citation needed]
Legal status
OTC in US
Purported mechanism
Docusate is an anionic surfactant that lowers the surface tension at the oil-water interface in the gut, allowing water and fats to penetrate stool and producing softer consistency without stimulating motility.0 Evidence for clinical benefit in routine constipation is surprisingly weak; multiple RCTs in hospitalized patients show no advantage over placebo. Continues to be widely used in practice (especially as adjunct to opioid-induced constipation regimens) despite the modest evidence base.

References